Gout Incidence Down With SGLT2 Inhibitors in Type 2 Diabetes
MONDAY, Jan. 13, 2020 -- Adults with type 2 diabetes newly prescribed a sodium-glucose cotransporter-2 (SGLT2) inhibitor have a lower incidence of gout than those prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2020 Category: Pharmaceuticals Source Type: news
Certain Diabetes Meds May Lower Gout Risk, Too
MONDAY, Jan. 13, 2020 -- Medications called SGLT2 inhibitors lower blood sugar in people with type 2 diabetes. And new research suggests these drugs may have an added benefit -- lowering the risk of gout.
Compared with people taking another class... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 13, 2020 Category: General Medicine Source Type: news
Dapagliflozin Granted Priority Review for Adults With Heart Failure Dapagliflozin Granted Priority Review for Adults With Heart Failure
The application for the SGLT2 inhibitor is based on the results from the landmark phase 3 DAPA-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 8, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
ADA Advises Wider Use of Newer Glucose-Lowering Drugs ADA Advises Wider Use of Newer Glucose-Lowering Drugs
In the 2020 Standards of Care, the American Diabetes Association advises consideration of SGLT2 inhibitors and GLP-1 receptor agonists in patients with high CVD or renal risk, regardless of A1c.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 20, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
SGLT2 inhibitors for diabetes are safe for older adults
According to a new study presented at the International Diabetes Federation (IDF) Congress 2019, SGLT2 inhibitors for the treatment of diabetes are safe and effective for older adults.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 20, 2019 Category: Endocrinology Source Type: news
SGLT2 Inhibitors for Diabetes Safe, Effective in Older Adults SGLT2 Inhibitors for Diabetes Safe, Effective in Older Adults
Real-world study suggests that they work just as well in adults aged 65 and older, although the genital-urinary infection rate was high.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 19, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Canagliflozin Helps Heart, Kidneys in'Well-Controlled' Diabetes Canagliflozin Helps Heart, Kidneys in'Well-Controlled' Diabetes
A subanalysis of CREDENCE suggests that SGLT2 inhibitor use should be based on clinical benefit, not solely glycemic control, say researchers. Another study hints that these drugs up EPO levels.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 10, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Highlights From ASN Kidney Week 2019 Highlights From ASN Kidney Week 2019
Highlights from ASN ' s Kidney Week 2019 include results from the CREDENCE trial showing benefit from the SGLT2 inhibitor canagliflozin for patients with established diabetic nephropathy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2019 Category: Consumer Health News Tags: Nephrology ReCAP Source Type: news
DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity
The SGLT2 inhibitor showed about the same effect on its clinical primary end point in the very elderly and across all degrees of symptom status at baseline in two new analyses.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 25, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family
' What I don ' t want to see is slow uptake, once it gets the indication in nondiabetics, ' said one physician. Think of SGLT2 inhibitors the same way as ACE inhibitors, beta blockers, and other HF drugs.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 19, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Newer Diabetes Drugs Given to Those Who Need Them Least Newer Diabetes Drugs Given to Those Who Need Them Least
' The challenge we have [is that] SGLT2 inhibitors are currently underprescribed, and when they are prescribed, ' they ' re not given to those patients likely to benefit most, says one expert.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 24, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Diabetes drugs may lower risk of dementia
Diabetes drugs such as SGLT2 inhibitors and metformin, may lower risk of dementia in patients with type 2 diabetes, according to a Danish study published in theEuropean Journal of Endocrinology.Speciality Medical Dialogues (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 23, 2019 Category: Endocrinology Source Type: news
SGLT2 Inhibitors Protect Against Kidney Disease in T2DM
THURSDAY, Oct. 10, 2019 -- A class of diabetes drugs, called sodium-glucose co-transporter-2 (SGLT2) inhibitors, protect against kidney disease in patients with type 2 diabetes, according to a review published online Sept. 5 in The Lancet Diabetes... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 10, 2019 Category: Pharmaceuticals Source Type: news
Sep 27 2019 This Week in Cardiology Sep 27 2019 This Week in Cardiology
Social effects of medicine, SGLT2 inhibitors, CIED infections, equity in cardiology, and post-PCI anti-thrombotic therapy are the topics discussed by Dr John Mandrola in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 27, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news
SGLT2 Inhibitors Linked to Lower Risk for Heart Failure
WEDNESDAY, Sept. 18, 2019 -- Use of sodium glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes is associated with a reduced risk for heart failure, but not a reduced risk for major cardiovascular events, compared with use of dipeptidyl... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2019 Category: Pharmaceuticals Source Type: news
